Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan

Journal of the Formosan Medical Association

Volumn 111, Issue 10, 2012, Pages 527-535

  Hsu, Ching Sheng ^a,b,c   Kao, Jia Horng ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ALT; APASL; CHB C; Fatty liver; HB CV; HCC; Hepatitis B virus; Hepatitis C virus; HOMA IR; Metabolic syndrome; MetS; NAFLD; NASH; T2DM; Taiwan

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN; ROSIGLITAZONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; HEPATITIS C; HUMAN; KINESIOTHERAPY; LAPAROSCOPY; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PREVALENCE; REVIEW; RISK; SOUTHEAST ASIA; TAIWAN; VIRUS HEPATITIS;

FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; RISK FACTORS; TAIWAN;

EID: 84867899419     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2012.07.002     Document Type: Review

References (59)

1. Schwenzer N.F., Springer F., Schraml C., Stefan N., Machann J., Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009, 51:433-445.
2. Farrell G.C. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol 2003, 18:124-138.
3. Chitturi S., Farrell G.C., George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?. J Gastroenterol Hepatol 2004, 19:368-374.
4. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
5. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
6. Argo C.K., Caldwell S.H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009, 13:511-531.
7. Chen C.H., Huang M.H., Yang J.C., Nien C.K., Yang C.C., Yeh Y.H., et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006, 40:745-752.
8. Lin T.J., Lin C.L., Wang C.S., Liu S.O., Liao L.Y. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan. World J Gastroenterol 2005, 11:3905-3908.
9. Tung T.H., Chang T.H., Chiu W.H., Lin T.H., Shih H.C., Chang M.H., et al. Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: experience at a teaching hospital. BMC Res Notes 2011, 4:315.
10. Hsiao T.J., Chen J.C., Wang J.D. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004, 28:167-172.
11. Serfaty L., Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008, 34:634-637.
12. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
13. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
14. Fusamoto H., Suzuki K., Hayashi N., Sasaki Y., Kono M., Kasahara A., et al. Obesity and liver disease: evaluation of fatty infiltration of the liver using ultrasonic attenuation. J Nutr Sci Vitaminol (Tokyo) 1991, 37:S71-S77.
15. Chan H.L., de Silva H.J., Leung N.W., Lim S.G., Farrell G.C. How should we manage patients with non-alcoholic fatty liver disease in 2007?. J Gastroenterol Hepatol 2007, 22:801-808.
16. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53:372-384.
17. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
18. Farrell G.C., Chitturi S., Lau G.K., Sollano J.D. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007, 22:775-777.
19. Yoon K.H., Lee J.H., Kim J.W., Cho J.H., Choi Y.H., Ko S.H., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.
20. Amarapurkar D.N., Hashimoto E., Lesmana L.A., Sollano J.D., Chen P.J., Goh K.L. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol 2007, 22:788-793.
21. Guha I.N., Parkes J., Roderick P.R., Harris S., Rosenberg W.M. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006, 55:1650-1660.
22. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
23. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
24. Fan J.G., Zhu J., Li X.J., Chen L., Lu Y.S., Li L., et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005, 20:1825-1832.
25. Kojima S., Watanabe N., Numata M., Ogawa T., Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003, 38:954-961.
26. Huang H.L., Lin W.Y., Lee L.T., Wang H.H., Lee W.J., Huang K.C. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007, 17:1457-1463.
27. Chiu C.C., Lee W.J., Wang W., Lee Y.C., Huang M.T. Correlations of laparoscopy with histology and laboratory studies on liver diseases in bariatric patients. Obes Surg 2008, 18:204-211.
28. Fu C.C., Chen M.C., Li Y.M., Liu T.T., Wang L.Y. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents. Ann Acad Med Singap 2009, 38:15-17.
29. Chen C.H., Huang M.H., Yang J.C., Nien C.K., Yang C.C., Yeh Y.H., et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007, 22:1482-1489.
30. Hsiao P.J., Kuo K.K., Shin S.J., Yang Y.H., Lin W.Y., Yang J.F., et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007, 22:2118-2123.
31. Tsai C.H., Li T.C., Lin C.C. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J 2008, 101:900-905.
32. Liu C.J., Jeng Y.M., Chen P.J., Lai M.Y., Yang H.C., Huang W.L., et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antivir Ther 2005, 10:405-415.
33. Day C.P., James O.F. Hepatic steatosis: innocent bystander or guilty party?. Hepatology 1998, 27:1463-1466.
34. Pan M., Cederbaum A.I., Zhang Y.L., Ginsberg H.N., Williams K.J., Fisher E.A. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004, 113:1277-1287.
35. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
36. Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738-744.
37. Kodama Y., Kisseleva T., Iwaisako K., Miura K., Taura K., De Minicis S., et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 2009, 137:1467-1477. e5.
38. Marra F., Gastaldelli A., Svegliati Baroni G., Tell G., Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008, 14:72-81.
39. Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
40. Chu C.J., Lu R.H., Wang S.S., Chang F.Y., Lin S.Y., Yang C.Y., et al. Plasma levels of interleukin-6 and interleukin-8 in Chinese patients with non-alcoholic fatty liver disease. Hepatogastroenterology 2007, 54:2045-2048.
41. Chu C.J., Lu R.H., Wang S.S., Chang F.Y., Wu S.L., Lu C.L., et al. Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha. Hepatogastroenterology 2007, 54:2099-2102.
42. Hsiao P.J., Hsieh T.J., Kuo K.K., Hung W.W., Tsai K.B., Yang C.H., et al. Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. BMC Mol Biol 2008, 9:82.
43. Lin H.Y., Yu I.C., Wang R.S., Chen Y.T., Liu N.C., Altuwaijri S., et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 2008, 47:1924-1935.
44. Yeh S.L., Lin M.T., Chen W.J. MCT/LCT emulsion ameliorate liver fat deposition in insulin-treated diabetic rats receiving total parenteral nutrition. Clin Nutr 1998, 17:273-277.
45. Chen W.L., Wei H.W., Chiu W.Z., Kang C.H., Lin T.H., Hung C.C., et al. Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens. Eur J Pharmacol 2011, 671:107-112.
46. Amali A.A., Rekha R.D., Lin C.J., Wang W.L., Gong H.Y., Her G.M., et al. Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J Biomed Sci 2006, 13:225-232.
47. Her G.M., Hsu C.C., Hong J.R., Lai C.Y., Hsu M.C., Pang H.W., et al. Overexpression of gankyrin induces liver steatosis in zebrafish (Danio rerio). Biochim Biophys Acta 2011, 1811:536-548.
48. Lin W.Y., Huang C.H. Fatty acid composition and lipid peroxidation of soft-shelled turtle, Pelodiscus sinensis, fed different dietary lipid sources. Comp Biochem Physiol C Toxicol Pharmacol 2007, 144:327-333.
49. Hsu C.S., Liu C.J., Liu C.H., Wang C.C., Chen C.L., Lai M.Y., et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008, 28:271-277.
50. Bellentani S., Dalle Grave R., Suppini A., Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008, 47:746-754.
51. Wang C.H., Leung C.H., Liu S.C., Chung C.H. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. J Formos Med Assoc 2006, 105:743-752.
52. Chen S.M., Liu C.Y., Li S.R., Huang H.T., Tsai C.Y., Jou H.J. Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease. J Chin Med Assoc 2008, 71:551-558.
53. Tseng P.H., Liu C.J., Kao J.H., Shun C.T., Chen P.J., Chen D.S. Disease progression in a patient with nonalcoholic steatohepatitis. J Formos Med Assoc 2008, 107:816-821.
54. Sebastiani G., Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006, 12:3682-3694.
55. Poynard T., Ratziu V., Charlotte F., Messous D., Munteanu M., Imbert-Bismut F., et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:34.
56. Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:6.
57. Chen C.L., Yang H.I., Yang W.S., Liu C.J., Chen P.J., You S.L., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
58. Hsu C.S., Liu C.J., Liu C.H., Chen C.L., Lai M.Y., Chen P.J., et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int 2008, 2:250-257.
59. Corey K.E., Kane E., Munroe C., Barlow L.L., Zheng H., Chung R.T. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009, 50:1030-1037.